Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.40 |
| ▸ | CTSC | P53634 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2074561 | 1.00 | USP30 (0.42) | USP30NPC1LMNANPSR1L3MBTL1 | |
| SCHEMBL2073456 | 0.87 | CTSC (0.42) | CTSC | |
| SCHEMBL2076012 | 0.85 | VHL (0.46) | USP30NPC1LMNANPSR1L3MBTL1 | |
| SCHEMBL2076014 | 0.85 | VHL (0.46) | USP30NPC1LMNANPSR1L3MBTL1 | |
| SCHEMBL12383351 | 0.85 | CTSC (0.53) | CTSC | |
| SCHEMBL2073444 | 0.85 | CTSC (0.48) | NPC1LMNANPSR1MEN1KMT2A | |
| SCHEMBL2073446 | 0.85 | CTSC (0.48) | NPC1LMNANPSR1MEN1KMT2A | |
| SCHEMBL2072370 | 0.82 | CTSC (0.47) | NPC1LMNANPSR1CTSC | |
| SCHEMBL2072367 | 0.82 | CTSC (0.47) | NPC1LMNANPSR1CTSC | |
| SCHEMBL3662047 | 0.81 | ALDH1A1 (0.44) | USP30NPC1LMNANPSR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201581-A1 | Novel Compounds 010 | ASTRAZENECA AB (SE) | 2011-08-18 | — | — | US | disclosed |
| US-7902181-B2 | Compounds 010 | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| US-20090306042-A1 | Novel Compounds 010 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306042-A1 | Novel Compounds 010 | MRGPRX2, F12, TBXA2R | USP30 3892/4885NPC1 628/4885LMNA 2051/4885 |
| US-20110201581-A1 | Novel Compounds 010 | MRGPRX2, F12, TBXA2R | USP30 3892/4885NPC1 628/4885LMNA 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.